CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 in New York.
The company's presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET for registered attendees. Management will also conduct one-on-one meetings with qualified investors during the conference. The webcast recording will remain accessible on the company's website for 90 days after the event.
CNS Pharmaceuticals (NASDAQ:CNSP), azienda biofarmaceutica impegnata nello sviluppo di terapie per tumori cerebrali e del sistema nervoso centrale, sar脿 presente al H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025 a New York.
La presentazione sar脿 fruibile tramite video webcast a partire dall'8 settembre 2025 alle 07:00 ET per i partecipanti registrati. La direzione terr脿 inoltre incontri individuali con investitori qualificati durante la conferenza. La registrazione del webcast rester脿 disponibile sul sito della societ脿 per 90 giorni dopo l'evento.
CNS Pharmaceuticals (NASDAQ:CNSP), una compa帽铆a biofarmac茅utica centrada en desarrollar tratamientos para c谩nceres cerebrales y del sistema nervioso central, participar谩 en el H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025 en Nueva York.
La presentaci贸n estar谩 disponible v铆a video webcast a partir del 8 de septiembre de 2025 a las 7:00 AM ET para los asistentes registrados. La direcci贸n tambi茅n mantendr谩 reuniones individuales con inversores calificados durante la conferencia. La grabaci贸n del webcast permanecer谩 accesible en la web de la compa帽铆a durante 90 d铆as tras el evento.
CNS Pharmaceuticals (NASDAQ:CNSP))電� 雵� 氚� 欷戩稊鞁犼步瓿� 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 氚旍澊鞓れ牅鞎届偓搿�, 2025雲� 9鞗� 8鞚茧秬韯� 10鞚缄箤歆� 雺挫殨鞐愳劀 鞐措Μ電� H.C. Wainwright 27th Annual Global Investment Conference鞐� 彀戈皜頃╇媹雼�.
須岇偓鞚� 氚滍憸電� 霌彪霅� 彀胳劃鞛愲ゼ 雽�靸侅溂搿� 2025雲� 9鞗� 8鞚� 鞓れ爠 7:00(ET)攵�韯� 牍勲敂鞓� 鞗轨簮鞀ろ姼搿� 鞁滌箔頃橃嫟 靾� 鞛堨姷雼堧嫟. 瓴届榿歆勳潃 旎嵓霟办姢 旮瓣皠 欷� 鞝侁博 韴瀽鞛愳檧鞚� 鞚茧寑鞚� 氙疙寘霃� 歆勴枆頃╇媹雼�. 鞗轨簮鞀ろ姼 雲鬼檾電� 頄夓偓 膦呺 頉� 90鞚缄皠 須岇偓 鞗轨偓鞚错姼鞐愳劀 瓿勳啀 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
CNS Pharmaceuticals (NASDAQ:CNSP), une soci茅t茅 biopharmaceutique d茅di茅e au d茅veloppement de traitements pour les cancers du cerveau et du syst猫me nerveux central, participera au H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025 脿 New York.
La pr茅sentation sera accessible en webcast vid茅o 脿 partir du 8 septembre 2025 脿 7h00 ET pour les participants inscrits. La direction tiendra 茅galement des r茅unions individuelles avec des investisseurs qualifi茅s pendant la conf茅rence. L'enregistrement du webcast restera disponible sur le site de la soci茅t茅 pendant 90 jours apr猫s l'茅v茅nement.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien f眉r Hirn- und ZNS-Krebsarten spezialisiert hat, wird vom 8. bis 10. September 2025 in New York beim H.C. Wainwright 27th Annual Global Investment Conference vertreten sein.
Die Unternehmenspr盲sentation steht registrierten Teilnehmern ab dem 8. September 2025 um 07:00 Uhr ET per Video-Webcast zur Verf眉gung. Das Management wird w盲hrend der Konferenz au脽erdem Einzelgespr盲che mit qualifizierten Investoren f眉hren. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung auf der Website des Unternehmens abrufbar.
- None.
- None.
HOUSTON, TX / / September 3, 2025 / ) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference .
A of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the page in the section of the Company's website (). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit , and connect with the Company on , , and.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original on ACCESS Newswire
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the H.C. Wainwright Conference 2025?
How can investors access CNS Pharmaceuticals' (CNSP) H.C. Wainwright conference presentation?
How long will CNS Pharmaceuticals' (CNSP) conference presentation be available for viewing?
What type of meetings will CNS Pharmaceuticals (CNSP) management conduct at the conference?
